Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing immunologically-targeted therapeutics that modulate T cell function to treat immune-mediated diseases, inflammatory conditions, and cancers. The company's lead product, soquelitinib, is a selective oral inhibitor of interleukin-2 inducible T cell kinase designed to shift immune responses toward tumor-killing while reducing pro-inflammatory cytokine production; it is in Phase 3 trials for peripheral T cell lymphoma and Phase 1/2 trials for atopic dermatitis. Corvus also develops ciforadenant, an oral A2A receptor antagonist for combination immunotherapy in renal cell carcinoma, and mupadolimab, an anti-CD73 antibody for oncology and infectious diseases. The company generates no current revenue as a preclinical and clinical-stage enterprise but has licensed intellectual property from third parties with potential milestone payments and royalty streams; it outsources all manufacturing and operations through contract partners while maintaining internal research and development capabilities.